Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling. My life has changed ...

What is the survival rate for stage 4 non-small cell lung cancer? According to the American Cancer Society, the 5-year relative survival rate for stage 4 NSCLC is 9%. This survival rate is based ...

Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...

A recent analysis shows that additional invasive staging modalities lead to relevant changes in target volume in some patients with NSCLC but do not impact survival.

TAIPEI (Taiwan News) — A Taiwanese-led study published in Nature has found that small-cell lung cancer (SCLC) cells exhibit ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Chen, F. (2025) Advances in the Application of Deep Learning in Prognostic Models for Non-Small Cell Lung Cancer. Health, 17, ...

Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...